Judith S. Wolverton

518 total citations
11 papers, 457 citations indexed

About

Judith S. Wolverton is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Judith S. Wolverton has authored 11 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Judith S. Wolverton's work include Cancer therapeutics and mechanisms (9 papers), Acute Lymphoblastic Leukemia research (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Judith S. Wolverton is often cited by papers focused on Cancer therapeutics and mechanisms (9 papers), Acute Lymphoblastic Leukemia research (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Judith S. Wolverton collaborates with scholars based in United States, Italy and Denmark. Judith S. Wolverton's co-authors include Mary K. Danks, William T. Beck, D. Parker Suttle, Ronald L. Felsted, Jeffrey M. Trent, Ahmad R. Safa, Margaret C. Cirtain, Ryungsa Kim, Mei Chen and Christopher L. Morton and has published in prestigious journals such as Cytometry, Advances in pharmacology and Cytotechnology.

In The Last Decade

Judith S. Wolverton

11 papers receiving 439 citations

Peers

Judith S. Wolverton
Clara Lemos Netherlands
Yue-Li Sun China
Ioana Abraham China
Karen Fife United States
Gwan Sun Lee South Korea
V. Wiebe United States
Randall W. Steinkampf United States
Alejandro Losada Spain
Kazumi Sano Japan
Astrid Kimmig Germany
Clara Lemos Netherlands
Judith S. Wolverton
Citations per year, relative to Judith S. Wolverton Judith S. Wolverton (= 1×) peers Clara Lemos

Countries citing papers authored by Judith S. Wolverton

Since Specialization
Citations

This map shows the geographic impact of Judith S. Wolverton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith S. Wolverton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith S. Wolverton more than expected).

Fields of papers citing papers by Judith S. Wolverton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith S. Wolverton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith S. Wolverton. The network helps show where Judith S. Wolverton may publish in the future.

Co-authorship network of co-authors of Judith S. Wolverton

This figure shows the co-authorship network connecting the top 25 collaborators of Judith S. Wolverton. A scholar is included among the top collaborators of Judith S. Wolverton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith S. Wolverton. Judith S. Wolverton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Potter, Philip M., et al.. (1998). In situ subcellular localization of epitope-tagged human and rabbit carboxylesterases. Cytometry. 32(3). 223–232. 13 indexed citations
2.
Potter, Philip M., Judith S. Wolverton, Christopher L. Morton, Monika Wierdl, & Mary K. Danks. (1998). Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme.. PubMed. 58(16). 3627–32. 68 indexed citations
3.
Beck, William T., et al.. (1997). Novel mechanisms of resistance to inhibitors of DNA topoisomerases. Advances in Enzyme Regulation. 37. 17–26. 6 indexed citations
4.
Danks, Mary K., et al.. (1997). Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.. PubMed. 3(10). 1731–8. 18 indexed citations
5.
Beck, William T., Mary K. Danks, Judith S. Wolverton, et al.. (1994). Resistance of Mammalian Tumor Cells to Inhibitors of DNA Topoisomerase II. Advances in pharmacology. 145–169. 34 indexed citations
6.
Beck, William T., Mary K. Danks, Judith S. Wolverton, Ryungsa Kim, & Mei Chen. (1993). Drug resistance associated with altered DNA topoisomerase II. Advances in Enzyme Regulation. 33. 113–116. 71 indexed citations
7.
Beck, William T., Mary K. Danks, Judith S. Wolverton, et al.. (1993). Altered DNA topoisomerase II in multidrug resistance. Cytotechnology. 11(2). 115–119. 21 indexed citations
8.
Wolverton, Judith S., Mary K. Danks, Bernd Granzen, & William T. Beck. (1992). DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.. PubMed. 52(15). 4248–53. 19 indexed citations
9.
Ubezio, Paolo, Maurizio D’Incalci, Giovanna Damia, et al.. (1989). Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia. European Journal of Cancer and Clinical Oncology. 25(12). 1895–1897. 23 indexed citations
10.
Wolverton, Judith S., Mary K. Danks, Carolin Schmidt, & William T. Beck. (1989). Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.. PubMed. 49(9). 2422–6. 27 indexed citations
11.
Beck, William T., Margaret C. Cirtain, Mary K. Danks, et al.. (1987). Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.. PubMed. 47(20). 5455–60. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clara Lemos Breakdown of academic impact, for papers by Yue-Li Sun Breakdown of academic impact, for papers by Ioana Abraham Breakdown of academic impact, for papers by Karen Fife Breakdown of academic impact, for papers by Gwan Sun Lee Breakdown of academic impact, for papers by V. Wiebe Breakdown of academic impact, for papers by Randall W. Steinkampf Breakdown of academic impact, for papers by Alejandro Losada Breakdown of academic impact, for papers by Kazumi Sano Breakdown of academic impact, for papers by Astrid Kimmig
Rankless by CCL
2026